A recent study demonstrated that genetically engineered umbilical cord MSCs by using recombinant TRAIL (rhTRAIL) have been designed to continuously express and secrete soluble TRAIL (MSC-sTRAIL) as a potential therapeutic approach for treatment of hematologic disorder B-cell acute lymphocytic leukemia (B-ALL). Here, TNFSF10 is linked to acute lymphoblastic leukemia.